FGF21 and Hepatic steatosis: Additionally, for 11 weeks, subcutaneous injection of B1344 (another analog of FGF21) significantly reduced hepatic steatosis, inflammation and fibrosis in cynomolgus monkeys suffering from nonalcoholic fatty liver disease (NAFLD), and an evaluation of FGF21 analog administration in nonhuman primate species undergoing liver biopsies for the treatment of NAFLD is first reported in this study [217].